Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China

Yingzhou Fu, Zhengxiong Li, Qiao Xia, Xiaojuan Chen, Zuojuan Xiang

Open source

DOI: 10.3389/fphar.2026.1864488
Published: 2026-07-02
Container: Frontiers in Pharmacology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1864488,
  title = {Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China},
  author = {Yingzhou Fu and Zhengxiong Li and Qiao Xia and Xiaojuan Chen and Zuojuan Xiang},
  year = {2026},
  journal = {Frontiers in Pharmacology},
  doi = {10.3389/fphar.2026.1864488},
  url = {https://doi.org/10.3389/fphar.2026.1864488}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China
AU  - Yingzhou Fu
AU  - Zhengxiong Li
AU  - Qiao Xia
AU  - Xiaojuan Chen
AU  - Zuojuan Xiang
PY  - 2026
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1864488
UR  - https://doi.org/10.3389/fphar.2026.1864488
ER  -

APA

Fu, Y., Li, Z., Xia, Q., Chen, X., & Xiang, Z. (2026). Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1864488

Source records

crossref · retrieved 2026-11-08T22:34:48.443Z